2016 Press Releases

Keyword Search
 
December 20, 2016
Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute
SAN CARLOS, CA -- (Marketwired) -- 12/20/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that it has entered into a new three-year Sponsored Research Agreement with the H. Lee Moffitt Cancer Center and Research Institute. At the same time, Lion Biotechnologies also announced that it has entered into a Clinical Grant Agreement with the H. Lee Moff... More »
November 28, 2016
Lion Biotechnologies Announces New Manufacturing Services Agreement with WuXi AppTec
SAN CARLOS, CA -- (Marketwired) -- 11/28/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), announced today that it has entered into a new three-year Manufacturing Services Agreement (MSA) and related statements of work with WuXi AppTec, Inc. (WuXi AppTec) to manufacture and perform services related to the manufacture of the Company's autologous cell therapy product... More »
November 23, 2016
Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare Conference
SAN CARLOS, CA -- (Marketwired) -- 11/23/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that its President and Chief Executive Officer, Dr. Maria Fardis, and Chief Financial Officer, Greg Schiffman, will participate in a fireside chat at the upcoming 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 2:30 p.m. E.T. i... More »
November 23, 2016
Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare Conference
SAN CARLOS, CA -- (Marketwired) -- 11/23/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that its President and Chief Executive Officer, Dr. Maria Fardis, and Chief Financial Officer, Greg Schiffman, will participate in a fireside chat at the upcoming 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 2:30 p.m. E.T. i... More »
November 8, 2016
Lion Biotechnologies Presents Encouraging TIL Technology Data in Four Posters at 2016 SITC Annual Meeting
SAN CARLOS, CA -- (Marketwired) -- 11/08/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today reported encouraging data in four poster presentations at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs in National Harbor, Maryland taking place November 9-13, 2016. "The data to be presented at SITC is reflective of o... More »
November 4, 2016
Lion Biotechnologies Reports Third Quarter 2016 Financial Results and Provides Corporate Update
SAN CARLOS, CA -- (Marketwired) -- 11/04/16 -- Company appoints new CFO, Greg Schiffman CRADA with NCI extended for five more years Company entered into license agreement with Karolinska Institute/PolyBioCept AB Company to present four posters at upcoming SITC meeting Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel canc... More »
October 28, 2016
Lion Biotechnologies to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results on Friday, November 4, 2016
SAN CARLOS, CA -- (Marketwired) -- 10/28/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that it will report its third quarter 2016 financial and operating results before the open of the U.S. financial markets on Friday, November 4, 2016. Management will host a conference call and live audio webcast to discuss these results and provide a business ... More »
October 26, 2016
Lion Biotechnologies Announces Presentations at Upcoming SITC 31st Annual Meeting
SAN CARLOS, CA -- (Marketwired) -- 10/26/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that presentations related to the Company's TIL technology will be made at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting & Associated Programs, being held on November 9-13, 2016 in National Harbor, MD. Presentation... More »
October 3, 2016
Lion Biotechnologies Appoints Gregory Schiffman as Chief Financial Officer
NEW YORK, NY -- (Marketwired) -- 10/03/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced the appointment of Gregory T. Schiffman, MBA as Chief Financial Officer of the company, effective immediately. "As we continue to build the management team into a fully integrated oncology organization, we are delighted to welcome Greg to the team," said Lion Biot... More »
September 15, 2016
Lion Biotechnologies Enters Into Exclusive License Agreement With PolyBioCept AB and Clinical Trials Agreement With the Karolinska University Hospital
License Grants Lion Worldwide Rights to a New Combination of Cytokines for TIL Manufacturing in Multiple Cancer Indications; Lion Financially Supports Two Clinical Trials in Glioblastoma and Pancreatic Cancer NEW YORK, NY -- (Marketwired) -- 09/15/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has entered into an exclusive license agreement with... More »
August 24, 2016
Lion Biotechnologies Announces 5-Year Extension of National Cancer Institute CRADA for Development of Novel TIL Immuno-Oncology Therapies
NEW YORK, NY -- (Marketwired) -- 08/24/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced an amendment of its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to extend the CRADA for an additional five-year term until 2021. Under the extended CRADA, the Company will continue working with Steven A. Rosenberg, M.D.... More »
August 8, 2016
Lion Biotechnologies Announces Second Quarter 2016 Financial Results
NEW YORK, NY -- (Marketwired) -- 08/08/16 -- Company appointed new CEO, Maria Fardis, Ph.D., with deep oncology leadership experience Completed $100M equity financing and expanded Board Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today reported its second quarter 2016 financial results and provided a c... More »
June 8, 2016
Lion Biotechnologies Announces Closing of $100 Million Private Financing
NEW YORK, NY -- (Marketwired) -- 06/08/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO) announced today the closing of its previously announced private financing with institutional and other accredited investors. Lion Biotechnologies received gross proceeds of $100 million, before paying the placement agents' fees and estimated offering expenses payable by the Company. At the closing, the Company issued 9,684,000 shares of common stock and 11,368,633 shares of its new non-voting Seri... More »
June 8, 2016
Lion Biotechnologies' Annual Meeting Rescheduled
NEW YORK, NY -- (Marketwired) -- 06/08/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that its Board of Directors will reschedule the company's 2016 Annual Meeting of Stockholders, which was originally scheduled for Friday, June 10, 2016. The company's Board of Directors recently appointed two new directors, and intends to appoint a third new direct... More »
June 3, 2016
Lion Biotechnologies Raises Approximately $100 Million in Private Placement
NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO) today announced that it has entered into a securities purchase agreement with institutional and other accredited investors under which the investors have agreed to purchase a total of 9,684,000 shares of common stock and approximately 11,368,500 shares of newly authorized Series B Preferred Stock in a private placement for aggregate gross proceeds of approximately $100.0 million. The purchas... More »
June 3, 2016
Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO
NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Dr. Fardis brings extensive experience in novel oncology drug development Company agrees to $100 million in equity  financing led by Quogue Capital, OrbiMed Advisors, Frazier Healthcare Partners and Broadfin Capital Wayne Rothbaum and Iain Dukes, D.Phil.... More »
June 3, 2016
Lion Biotechnologies to Present at the Jefferies 2016 Healthcare Conference
NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced today that Lion management will present a company overview at the upcoming Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2:30pm E.T in New York, NY. A live webcast of the presentation will be available by visiting the Investors section of Lion Biot... More »
May 9, 2016
Lion Biotechnologies Announces First Quarter 2016 Financial Results
NEW YORK, NY -- (Marketwired) -- 05/09/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today reported its first quarter 2016 financial results and provided a corporate update. For the first quarter ended March 31, 2016, Lion reported research and development expenses of $4.2 million, compared to $2.4 million for the same period in 2015. The increase in research ... More »
April 17, 2016
Lion Biotechnologies Manufacturing Capabilities and Research Programs Unaffected by Review of National Cancer Institute's Manufacturing Facilities
Lion's Phase 2 study of lead product, LN-144, for the treatment of refractory, metastatic melanoma continues uninterrupted NEW YORK, NY -- (Marketwired) -- 04/17/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), announced that it has learned that the cell therapy manufacturing facilities at the National Cancer Institute (NCI) are undergoing a voluntary int... More »
March 28, 2016
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
NEW YORK, NY -- (Marketwired) -- 03/28/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Michael T. Lotze, MD, as chief scientific officer (CSO) and vice president of research and development, effective immediately. A renowned expert in immuno-oncology with more than 35 years of clinical experience, Dr. Lotze joins the c... More »
March 10, 2016
Lion Biotechnologies Announces 2015 Fourth-Quarter and Year-End Financial Results
NEW YORK, NY -- (Marketwired) -- 03/10/16 --  Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today reported year-end and fourth-quarter financial results. For the fourth quarter and year ended December 31, 2015, the company reported research and development expenses of $5.1 million and $15.5 million, respectively, compared to $2.7 million and $3.8 million, res... More »
March 7, 2016
Lion Biotechnologies to Participate in Upcoming Conferences
NEW YORK, NY -- (Marketwired) -- 03/07/16 -- Lion Biotechnologies, (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that President and Chief Executive Officer, Elma Hawkins, PhD, will participate in the following upcoming conferences: Cowen and Company 36th Annual Health Care Conference Date: Wednesday, March 9, 2016 Location: Boston Marriott... More »
February 4, 2016
Lion Biotechnologies Names Steven A. Fischkoff Chief Medical Officer
NEW YORK, NY -- (Marketwired) -- 02/04/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Steven A. Fischkoff, MD, as chief medical officer (CMO), effective immediately. With 25 years of biopharmaceutical experience, Dr. Fischkoff most recently served as vice president of clinical and medical affairs at Celgene Cellular ... More »
February 1, 2016
Lion Biotechnologies Announces Allowance of IND Application to Begin Clinical Trials in Cervical, Head and Neck Cancers
NEW YORK, NY -- (Marketwired) -- 02/01/16 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC). Each of the single-a... More »
January 4, 2016
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer
NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has filed an investigational new drug (IND) application with the United States Food and Drug Administration to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC). "This IND filing re... More »